Our editorial staff has gathered information from annual reports, interviews, and analyst coverage to compile a list of the previous year's Top 20 players in the Pharma arena.
|
The Top 10 Biopharma rankings saw two more companies reach the billion-dollar mark in revenues in 2004, as Gilead and MedImmune crossed that threshold. Unfortunately, a bad case of the flu sent Chiron back under the billion-dollar mark, as its fluvirin vaccine revenues dropped from $219 million in 2003 to a mere $2 million last year, after its well-documented manufacturing problems.
|
